HC Wainwright reiterated their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a report published on Monday morning, AnalystRatings.com reports. HC Wainwright currently has a $22.00 target price on the stock.
“With the stock above our $22 price target, we await progress from its other pipeline initiatives including potential IND clearance to make adjustments to our model.”,” the firm’s analyst wrote.
A number of other equities analysts have also commented on the company. BTIG Research cut their price objective on Voyager Therapeutics to $23.00 and set a positive rating on the stock in a research note on Tuesday, January 8th. Cowen reaffirmed a buy rating on shares of Voyager Therapeutics in a research note on Wednesday, February 27th. Cantor Fitzgerald initiated coverage on Voyager Therapeutics in a research note on Tuesday, March 5th. They issued an overweight rating and a $27.00 price objective on the stock. ValuEngine lowered Voyager Therapeutics from a hold rating to a sell rating in a research note on Monday, February 4th. Finally, Zacks Investment Research raised Voyager Therapeutics from a hold rating to a buy rating and set a $9.50 price objective on the stock in a research note on Saturday, January 19th. Three research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $24.11.
Voyager Therapeutics stock opened at $24.04 on Monday. The company has a market capitalization of $829.06 million, a P/E ratio of -8.74 and a beta of 2.82. Voyager Therapeutics has a one year low of $7.76 and a one year high of $24.60.
Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Tuesday, February 26th. The company reported ($0.70) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.66) by ($0.04). The company had revenue of $2.01 million during the quarter, compared to analyst estimates of $2.90 million. Voyager Therapeutics had a negative return on equity of 120.82% and a negative net margin of 1,158.79%. Analysts predict that Voyager Therapeutics will post -2.79 EPS for the current year.
In other Voyager Therapeutics news, major shareholder Neurocrine Biosciences Inc purchased 4,179,728 shares of the company’s stock in a transaction on Tuesday, March 12th. The shares were purchased at an average cost of $11.96 per share, with a total value of $49,989,546.88. Following the completion of the purchase, the insider now owns 4,179,728 shares in the company, valued at $49,989,546.88. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 33.60% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently modified their holdings of VYGR. BB Biotech AG increased its holdings in shares of Voyager Therapeutics by 1.5% during the fourth quarter. BB Biotech AG now owns 2,865,841 shares of the company’s stock valued at $26,939,000 after acquiring an additional 43,200 shares in the last quarter. BlackRock Inc. increased its holdings in shares of Voyager Therapeutics by 1.0% during the third quarter. BlackRock Inc. now owns 1,863,766 shares of the company’s stock valued at $35,262,000 after acquiring an additional 18,060 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Voyager Therapeutics by 10.5% during the third quarter. Vanguard Group Inc. now owns 1,196,594 shares of the company’s stock valued at $22,640,000 after acquiring an additional 113,442 shares in the last quarter. Vanguard Group Inc increased its holdings in shares of Voyager Therapeutics by 10.5% during the third quarter. Vanguard Group Inc now owns 1,196,594 shares of the company’s stock valued at $22,640,000 after acquiring an additional 113,442 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Voyager Therapeutics by 23.1% during the fourth quarter. Geode Capital Management LLC now owns 287,264 shares of the company’s stock valued at $2,700,000 after acquiring an additional 53,888 shares in the last quarter. 75.49% of the stock is currently owned by hedge funds and other institutional investors.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.
Featured Article: Market Capitalization in the Stock Market
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.